Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

NCT01702467 | Completed Phase 1

• 1 other identifier: 116698
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

The current study will examine the safety, tolerability, plasma pharmacokinetics (PK), and plasma pharmacodynamics (PD) of single-doses of GSK2647544.The study will be conducted as a randomized, single-blind, placebo controlled, 4-way crossover single oral ascending dose design in 2 independent cohorts, eight healthy male subjects in each of the cohorts. Each potential subject will undergo Screening visit, Treatment Phase and Follow-up visit.

Conditions

Alzheimer's Disease

Keywords

Lp-PLA2; Alzheimer's disease

Outcome Measures

Primary Outcomes (6)

• Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s

  Safety and tolerability parameters will include recording of AEs

  5 days in each of the 4 dosing session

• Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values

  Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis) values at Screening, Day -1, Day 3 and Follow-up (7-14 days post-last dose)

  5 days in each of the 4 dosing session

• Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings

  Safety and tolerability parameter will include the electrocardiogram (ECG) readings at Screening, Day -1, Day 1, Day 2, Day 3 and Follow-up (7-14 days post-last dose)

  5 days in each of the 4 dosing session

• Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters

  Safety and tolerability parameter will include the Telemetry ECG readings from 30 minutes pre-dosing till 48 hours post-dosing

  3 Days in each of the 4 dosing session

• Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs

  Vital signs measurement include systolic and diastolic blood pressure and pulse rate at Screening, Day -1, Day 1, Day 2, Day 3, Day 4 and Follow-up (7-14 days post-last dose)

  5 days in each of the 4 dosing session

• Safety and tolerability of GSK2647544 as assessed by using the Columbia Suicide Severity Rating Scale (C-SSRS)

  C-SSRS will be measured at Screening, Day -1, Day 1 (conducted prior to discharge) and Follow-up (7-14 days post-last dose)

  5 days in each of the 4 dosing session

Secondary Outcomes (6)

• Peak plasma concentration (Cmax) of GSK2647544

  4 Days in each of the 4 dosing session

• Time of peak plasma concentration (tmax) of GSK2647544

  4 Days in each of the 4 dosing session

• Area under the time concentration curve (AUC) of GSK2647544

  4 Days in each of the 4 dosing session

• Terminal half-life (t½ ) of GSK2647544

  4 Days in each of the 4 dosing session

• Apparent oral clearance (CL/F) of GSK2647544

  4 Days in each of the 4 dosing session

Study Arms (2)

GSK2647544

EXPERIMENTAL

The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).

Drug: GSK2647544

Placebo

PLACEBO COMPARATOR

Matching placebo

Drug: Placebo

Interventions

GSK2647544 DRUG

Capsules containing 0.5mg to 50mg of GSK2647544.

GSK2647544

Placebo DRUG

Matching placebo capsules.

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males who are 18 to 55 years of age, inclusive
• Healthy as determined by a responsible and experienced physician
• aspartate aminotransferase (AST), Alanine transaminase (ALT), alkaline phosphatase and bilirubin \<= 1.5xUpper Limit of Normal (ULN)
• Average of triplicate QTcB values and average of triplicate QTcF values must both \< 450 millisecond (msec)
• Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19 and 30
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods
• Capable of giving written informed consent

You may not qualify if:

• Those with Lp-PLA2 activity \<=20 nanomole/minute/milliliter (mL)(for subjects with 2 known birth parents of at least 50% Japanese, Chinese, or Korean ancestry)
• History of asthma, anaphylaxis or anaphalactoid reactions, severe allergic responses
• History of hypercoagulable state or history of thrombosis
• A history of biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology
• Positive Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C at screening
• History of regular use of tobacco- or nicotine-containing products within three months of the study and/or has a positive breath CO at screening
• History of alcohol consumption exceeding, on average, 21 drinks/week for men (1 drink = 100 mL of wine or 240 mL of beer or 30 mL of hard liquor in Australia) within 6 months of the first dose of study medication
• Positive urine drug or positive breath alcohol test at screening or at admission to Clinical Research Unit
• Unable to refrain from use of prescription or non-prescription drugs and vitamins within 7 days or 5 half-lives (whichever is longer) prior to administration of study
• Unable to refrain from use of dietary/herbal supplements including (but not limited to) St. John's wort, kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, ginseng and red yeast rice within 14 days prior to treatment with study medication
• Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to dosing
• Unable to refrain from consumption of grapefruit or grapefruit juice within 7 days prior to the first dose of study medication
• For male subjects, an unwillingness to abstain from sexual intercourse with pregnant or lactating women or an unwillingness to use a condom plus partner use of a highly effective contraceptive if engaging in sexual intercourse with a woman who could become pregnant until discharge from the study
• Donation of blood in excess of 500 mL within 56 days prior to dosing
• History of sensitivity to heparin or heparin-induced thrombocytopenia

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Randwick, New South Wales, 2031, Australia

Location

Related Links

• Results for study 116698 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Alzheimer Disease

Interventions

GSK2647544

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2012
• First Posted: October 8, 2012
• Study Start: October 19, 2012
• Primary Completion: May 15, 2013
• Study Completion: May 15, 2013
• Last Updated: October 18, 2017

Record last verified: 2017-10

Data Sharing

• IPD Sharing: Will share

Locations

AU (1)